J. Hargreaves

发表

Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.

G. Tucker, A. Rostami-Hodjegan, M. Lennard, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA).

A. Rostami-Hodjegan, J. Swales, L. M. Van, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers

S. Oliver, H. Swaisland, M. Taboada, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

N. Carragher, P. Elvin, B. Davies, 2009, Molecular oncology.

The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

Amir Heydari, Amin Rostami-Hodjegan, Karen Rowland-Yeo, 2006, Journal of psychopharmacology.